Research Reference
CJC-1295 (No DAC)
Short-acting GHRH analog — pulsatile GH release (pair with GHRP)
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
CJC-1295 no DAC (also known as modified GRF 1-29) is a synthetic GHRH analog with four amino acid substitutions for improved stability and a short-acting ~30-minute half-life that produces pulsatile GH release mimicking the body's natural secretion pattern.
No human clinical trials exist for the no-DAC form. Community protocols are based on GHRH pharmacology and the DAC version's clinical data.
The standard protocol is 200 mcg before bed, 5 days on / 2 days off, for 8 weeks. CJC-1295 no DAC is almost always paired with a GHRP (ipamorelin, GHRP-2, or GHRP-6) for synergistic GH release. Community sources consistently describe standalone results as modest compared to GHRP-stacked protocols.
Side Effects & Safety
- Flushing/warmth — very common in first 1–2 weeks, transient (15–30 min post-injection)
- Head rush/dizziness — brief, typically resolves quickly
- Injection site reactions — mild redness, occasional irritation
- Water retention — mild, transient
- Numbness/tingling — occasional at higher doses
- Insulin sensitivity changes — GH affects glucose metabolism; monitor if relevant
No long-term trials have evaluated continuous use of the no-DAC form.
Research Basis
CJC-1295 clinical research primarily used the DAC version, but the pharmacology informs no-DAC protocols.
Pivotal human study (Teichman et al., 2006): Examined CJC-1295 (with DAC) in 36 healthy adults (21–61 years). Single doses of 30–120 mcg/kg produced dose-dependent GH and IGF-1 increases, with IGF-1 elevated 1.5–3 fold for 6–14 days.
Preserved pulsatility (Ionescu & Bhatt, 2006): A follow-up confirmed that despite continuous GHRH stimulation, pulsatile GH secretion was maintained — GH pulse frequency preserved with 2-fold increases in mean GH and pulse mass.
Animal studies (Alba et al., 2006): CJC-1295 normalized growth in GHRH knockout mice with once-daily dosing.
Why no-DAC is preferred by many: Short half-life produces pulsatile rather than sustained GH elevation, more closely mimicking natural GHRH/GH secretion. Lower baseline GH between pulses. Controllable timing windows. Optimal synergy with timed GHRP co-injection.